De COVID I2 study

This project has started in October 2020 and will last approximately two years. In total, 2200 patients with an immune-mediated inflammatory disease (for example rheumatoid arthritis) who use immunomodulatory medication will participate. It is uncertain whether it is best to continue or temporary interrupt immunomodulatory medication in case of an infection. To investigate this, participants will be divided into two groups: 1) Continuation of medication during an infection. 2) Temporary interruption of medication during an infection. In case of an infection, we will collect information on this infection and ask the participant to either continue or temporary interrupt their medication. The main outcome is the proportion of patients with a serious infection in both groups.